Barinthus Biotherapeutics (BRNS) Change in Account Payables (2020 - 2026)
Barinthus Biotherapeutics (BRNS) reported Change in Account Payables of $644000.0 for Q1 2026, up 155.76% on a YoY basis from $251800.9 in Q1 2025, and up 285.06% quarter-over-quarter from -$348000.0 in Q4 2025.
Barinthus Biotherapeutics (BRNS) Change in Account Payables (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics has reported Change in Account Payables for 7 years, with the latest figure at $644000.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables rose 155.76% year-over-year to $644000.0; the trailing twelve-month figure through Mar 2026 stood at -$403000.0 (down 250.94% YoY), and the FY2025 full-year result was -$2.2 million, down 345.21% from the prior year.
- Change in Account Payables for Q1 2026 stood at $644000.0, up from -$348000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $2.3 million in Q3 2023, with the low at -$3.8 million in Q4 2023.
- Historically, Change in Account Payables has averaged -$170470.6 across 5 years, with a median of -$348000.0 in 2025.
- Annual changes were most pronounced in 2022 — Change in Account Payables jumped 975.44% — and 2023, when it plunged 480.26%.
- Barinthus Biotherapeutics' Change in Account Payables stood at $998000.0 in 2022, then sank by 480.26% to -$3.8 million in 2023, then jumped by 87.88% to -$460000.0 in 2024, then gained by 24.35% to -$348000.0 in 2025, then jumped by 285.06% to $644000.0 in 2026.
- The last three Change in Account Payables figures came in at $644000.0 (Q1 2026), -$348000.0 (Q4 2025), and -$1.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -9.42 Mn |
| 10 | Barinthus Biotherapeutics | 27.57 Mn | -39.54 Mn | - | 644,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 644,000.00 |
| Mar 31, 2026 | 644,000.00 |
| Dec 31, 2025 | -348,000.00 |
| Dec 31, 2025 | -348,000.00 |
| Sep 30, 2025 | -1.04 Mn |
| Sep 30, 2025 | -1.04 Mn |
| Jun 30, 2025 | 342,000.00 |
| Jun 30, 2025 | 342,000.00 |
| Mar 31, 2025 | -1.16 Mn |
| Mar 31, 2025 | -1.16 Mn |
| Dec 31, 2024 | -460,000.00 |
| Dec 31, 2024 | -460,000.00 |
| Sep 30, 2024 | 391,000.00 |
| Sep 30, 2024 | 391,000.00 |
| Jun 30, 2024 | 1.49 Mn |
| Jun 30, 2024 | 1.49 Mn |
| Mar 31, 2024 | -524,000.00 |
| Mar 31, 2024 | -524,000.00 |
| Dec 31, 2023 | -3.80 Mn |
| Dec 31, 2023 | -3.80 Mn |